These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34833859)

  • 1.
    Vermathen M; von Tengg-Kobligk H; Hungerbühler MN; Vermathen P; Ruprecht N
    Molecules; 2021 Nov; 26(22):. PubMed ID: 34833859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the redox-active MnTnHex-2-PyP
    Soares RB; Pinto J; Amaro F; Manguinhas R; Gil N; Rosell R; Batinic-Haberle I; Fernandes AS; Oliveira NG; Guedes de Pinho P
    Biochem Pharmacol; 2024 Sep; 227():116424. PubMed ID: 39004232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond Single-Cell Analysis of Metallodrugs by ICP-MS: Targeting Cellular Substructures.
    Galé A; Hofmann L; Lüdi N; Hungerbühler MN; Kempf C; Heverhagen JT; von Tengg-Kobligk H; Broekmann P; Ruprecht N
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Profiling of Cells in Response to Drug Treatment using
    Vermathen M; Diserens G; Vermathen P; Furrer J
    Chimia (Aarau); 2017 Mar; 71(3):124-129. PubMed ID: 28351458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of chemotherapy on metabolic reprogramming: Characterization of the metabolic profile of breast cancer MDA-MB-231 cells using
    Maria RM; Altei WF; Selistre-de-Araujo HS; Colnago LA
    J Pharm Biomed Anal; 2017 Nov; 146():324-328. PubMed ID: 28915495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
    Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
    Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
    He Y; Xie H; Yu P; Jiang S; Wei L
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer.
    Sun Y; Bao X; Ren Y; Jia L; Zou S; Han J; Zhao M; Han M; Li H; Hua Q; Fang Y; Yang J; Wu C; Chen G; Wang L
    Cell Death Dis; 2019 May; 10(6):400. PubMed ID: 31127087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2.
    Wang D; Zhao C; Xu F; Zhang A; Jin M; Zhang K; Liu L; Hua Q; Zhao J; Liu J; Yang H; Huang G
    Theranostics; 2021; 11(6):2860-2875. PubMed ID: 33456577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emetine Synergizes with Cisplatin to Enhance Anti-Cancer Efficacy against Lung Cancer Cells.
    Wu TH; Chang SY; Shih YL; Huang TW; Chang H; Lin YW
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31775307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deoxyshikonin inhibits cisplatin resistance of non-small-cell lung cancer cells by repressing Akt-mediated ABCB1 expression and function.
    Zhang S; Wang Y
    J Biochem Mol Toxicol; 2020 Oct; 34(10):e22560. PubMed ID: 32627280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
    Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
    Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.
    Barr MP; Gray SG; Hoffmann AC; Hilger RA; Thomale J; O'Flaherty JD; Fennell DA; Richard D; O'Leary JJ; O'Byrne KJ
    PLoS One; 2013; 8(1):e54193. PubMed ID: 23349823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug resistant P-glycoprotein positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein-mediated drug efflux activity.
    Gibalová L; Sedlák J; Labudová M; Barancík M; Reháková A; Breier A; Sulová Z
    Gen Physiol Biophys; 2009 Dec; 28(4):391-403. PubMed ID: 20097962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer.
    Xiao L; Lan X; Shi X; Zhao K; Wang D; Wang X; Li F; Huang H; Liu J
    Cell Death Dis; 2017 May; 8(5):e2803. PubMed ID: 28518145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.
    Lo Iacono M; Monica V; Vavalà T; Gisabella M; Saviozzi S; Bracco E; Novello S; Papotti M; Scagliotti GV
    Int J Cancer; 2015 Jun; 136(11):2598-609. PubMed ID: 25359574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC.
    Wu C; Wang Y; Xia Y; He S; Wang Z; Chen Y; Wu C; Shu Y; Jiang J
    FEBS Lett; 2014 Dec; 588(24):4566-72. PubMed ID: 25447528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.